Skip to main content

Impact of hormone replacement therapy use on mammographic screening outcomes

Abstract

Purpose

This study aims to measure the impact of HRT use at the time of screening on rates of screen-detected invasive breast cancer (IBC) and ductal carcinoma in situ (DCIS), interval cancers and investigative procedures, within a well-established population-based mammography screening program.

Methods

Using South Australian BreastScreen data from 1998 to 2009 pertaining to 819,722 screening episodes, Poisson regression models were undertaken to estimate the incidence risk ratios (IRR) for various screening outcomes at both the first and subsequent screening rounds, among women who had been using HRT in the 6 months prior to screening compared with those who had not.

Results

Current HRT use was associated with increased risk of recall for assessment, biopsy procedures, and breast cancer diagnosis among BreastScreen participants. Risk of screen-detected breast cancer was increased at subsequent screening rounds (IRR = 1.30, 95 % confidence interval 1.18–1.34), but not at women’s first screening round (1.05, 0.88–1.25). This increased risk applied to IBC (1.35, 1.27–1.45), but not to DCIS (1.04, 0.89–1.23). Interval cancer risk was elevated among HRT users following both the first screen (1.77, 1.33–2.37) and subsequent screening episodes (1.92, 1.72–2.15).

Conclusions

Increased risks of recall, biopsy rates, screen-detected, and interval cancers among HRT users have important implications for population-based breast cancer screening programs. Our findings support the concept that HRT use may increase the growth of preexisting cancers. Lack of effect on DCIS could imply different etiology or time frames for DCIS and IBC development or increased transition from preinvasive to invasive disease due to HRT use.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289(24):3243–3253. doi:10.1001/jama.289.24.3243

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910–918. doi:10.1016/S1470-2045(06)70911-1

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92(4):328–332

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, Hollenbeck AR, Lacey JV Jr (2008) Menopausal hormone therapy and breast cancer risk in the NIH-AARP diet and health study cohort. Cancer Epidemiol Biomarkers Prev 17(11):3150–3160. doi:10.1158/1055-9965.EPI-08-0435

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289(24):3254–3263. doi:10.1001/jama.289.24.3254

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, Fabre A, Hemon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK, Bingham S, Khaw KT, Olsen A, Tjonneland A, Rodriguez L, Sanchez MJ, Etxezarreta PA, Ardanaz E, Tormo MJ, Peeters PH, van Gils CH, Steffen A, Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, Norat T, Riboli E, Panico S, Masala G, Gonzalez CA, Berrino F (2011) Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 128(1):144–156. doi:10.1002/ijc.25314

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Boyd NF, Martin LJ, Li Q, Sun L, Chiarelli AM, Hislop G, Yaffe MJ, Minkin S (2006) Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15(5):961–966. doi:10.1158/1055-9965.EPI-05-0762

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Hofvind S, Moller B, Thoresen S, Ursin G (2006) Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 118(12):3112–3117. doi:10.1002/ijc.21742

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Roman R, Sala M, Salas D, Ascunce N, Zubizarreta R, Castells X (2012) Effect of protocol-related variables and women’s characteristics on the cumulative false-positive risk in breast cancer screening. Ann Oncol 23(1):104–111. doi:10.1093/annonc/mdr032

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Kavanagh AM, Mitchell H, Giles GG (2000) Hormone replacement therapy and accuracy of mammographic screening. Lancet 355(9200):270–274. doi:10.1016/S0140-6736(99)07319-5

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Banks E (2001) Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 8(1):29–34

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Kavanagh AM, Cawson J, Byrnes GB, Giles GG, Marr G, Tong B, Gertig DM, Hopper JL (2005) Hormone replacement therapy, percent mammographic density, and sensitivity of mammography. Cancer Epidemiol Biomarkers Prev 14(5):1060–1064. doi:10.1158/1055-9965.EPI-04-0165

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, English R, Jackson A, Kutt E, Lavelle J, Rockall L, Wallis MG, Wilson M, Patnick J (2004) Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 329(7464):477. doi:10.1136/bmj.329.7464.477

    PubMed  Article  Google Scholar 

  14. 14.

    Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, English R, Jackson A, Kutt E, Lavelle J, Rockall L, Wallis MG, Wilson M, Patnick J (2004) Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the Million Women Study. BMJ 328(7451):1291–1292. doi:10.1136/bmj.328.7451.1291

    PubMed  Article  Google Scholar 

  15. 15.

    Chiarelli AM, Kirsh VA, Klar NS, Shumak R, Jong R, Fishell E, Yaffe MJ, Boyd NF (2006) Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection. Cancer Epidemiol Biomarkers Prev 15(10):1856–1862. doi:10.1158/1055-9965.EPI-06-0290

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Litherland JC, Stallard S, Hole D, Cordiner C (1999) The effect of hormone replacement therapy on the sensitivity of screening mammograms. Clin Radiol 54(5):285–288

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Virnig BA, Wang SY, Shamilyan T, Kane RL, Tuttle TM (2010) Ductal carcinoma in situ: risk factors and impact of screening. J Natl Cancer Inst Monogr 41:113–116. doi:10.1093/jncimonographs/lgq024

    Article  Google Scholar 

  18. 18.

    Calvocoressi L, Stowe MH, Carter D, Claus EB (2012) Postmenopausal hormone therapy and ductal carcinoma in situ: a population-based case-control study. Cancer Epidemiol 36(2):161–168. doi:10.1016/j.canep.2012.01.001

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Taylor AW, MacLennan AH, Avery JC (2006) Postmenopausal hormone therapy: who now takes it and do they differ from non-users? Aust N Z J Obstet Gynaecol 46(2):128–135. doi:10.1111/j.1479-828X.2006.00542.x

    PubMed  Article  Google Scholar 

  20. 20.

    Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative group on hormonal factors in breast cancer. Lancet 350(9084):1047–1059

    Article  Google Scholar 

  21. 21.

    Zbuk K, Anand SS (2012) Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health 66(1):1–7. doi:10.1136/jech.2008.083774

    PubMed  Article  Google Scholar 

  22. 22.

    MacLennan AH, Gill TK, Broadbent JL, Taylor AW (2009) Continuing decline in hormone therapy use: population trends over 17 years. Climacteric 12(2):122–130. doi:10.1080/13697130802666251

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Roman R, Sala M, De La Vega M, Natal C, Galceran J, Gonzalez-Roman I, Baroja A, Zubizarreta R, Ascunce N, Salas D, Castells X (2011) Effect of false-positives and women’s characteristics on long-term adherence to breast cancer screening. Breast Cancer Res Treat 130(2):543–552. doi:10.1007/s10549-011-1581-4

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    BreastScreen SA (2010) The impact of BreastScreen SA, 20 year report 1989–2008: with trend data for 1989–2004. Government of South Australia Adelaide

  25. 25.

    National Breast Cancer Centre (2002) Breast imaging: a guide for practice. National Breast Cancer Centre Camperdown NSW

  26. 26.

    Australian Bureau of Statistics (2008) Information paper: an introduction to socio-economic indexes for areas (SEIFA), 2006 ABS, Canberra

  27. 27.

    Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702–706

    PubMed  Article  Google Scholar 

  28. 28.

    StataCorp (2010) Stata statistical software: release 12. StatCorp LP, College Station

    Google Scholar 

  29. 29.

    Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573–587. doi:10.1056/NEJMoa0807684

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Henrich JB, Kornguth PJ, Viscoli CM, Horwitz RI (1998) Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 51(12):1277–1283

    PubMed  Article  CAS  Google Scholar 

  31. 31.

    Persson I, Thurfjell E, Bergstrom R, Holmberg L (1997) Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 72(5):758–761. doi:10.1002/(SICI)1097-0215(19970904)72:5<758:AID-IJC9>3.0.CO;2-R

    PubMed  Article  CAS  Google Scholar 

  32. 32.

    Kavanagh AM, Davidson N, Jolley D, Heuzenroeder L, Chapman A, Evans J, Gertig DM, Amos A (2006) Determinants of false positive recall in an Australian mammographic screening program. Breast 15(4):510–518. doi:10.1016/j.breast.2005.09.006

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Kavanagh AM, Giles GG, Mitchell H, Cawson JN (2000) The sensitivity, specificity, and positive predictive value of screening mammography and symptomatic status. J Med Screen 7(2):105–110

    PubMed  Article  CAS  Google Scholar 

  34. 34.

    Sweeney KJ, Boran S, Fitzpatrick P, Merrigan AB, Moran R, Flanagan F, Kerin MJ (2009) Postmenopausal hormone therapy and prevalent round screening mammography. Int J Cancer 124(6):1490–1491. doi:10.1002/ijc.24081

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Dietel M (2010) Hormone replacement therapy (HRT), breast cancer and tumor pathology. Maturitas 65(3):183–189. doi:10.1016/j.maturitas.2009.11.005

    PubMed  Article  CAS  Google Scholar 

  36. 36.

    Seradour B, Esteve J, Heid P, Jacquemier J (1999) Hormone replacement therapy and screening mammography: analysis of the results in the Bouches du Rhone programme. J Med Screen 6(2):99–102

    PubMed  Article  CAS  Google Scholar 

  37. 37.

    Crouchley K, Wylie E, Khong E (2006) Hormone replacement therapy and mammographic screening outcomes in Western Australia. J Med Screen 13(2):93–97. doi:10.1258/096914106777589588

    PubMed  Article  Google Scholar 

  38. 38.

    Warren R (2004) Hormones and mammographic breast density. Maturitas 49(1):67–78. doi:10.1016/j.maturitas.2004.06.013

    PubMed  Article  CAS  Google Scholar 

  39. 39.

    Weedon-Fekjaer H, Tretli S, Aalen OO (2010) Estimating screening test sensitivity and tumour progression using tumour size and time since previous screening. Stat Methods Med Res 19(5):507–527. doi:10.1177/0962280209359860

    PubMed  Article  Google Scholar 

  40. 40.

    Santen RJ, Yue W, Heitjan DF (2012) Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev 21(7):1038–1048. doi:10.1158/1055-9965.EPI-12-0043

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. JAMA 281(22):2091–2097

    PubMed  Article  CAS  Google Scholar 

  42. 42.

    Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274(2):137–142

    PubMed  Article  CAS  Google Scholar 

  43. 43.

    Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295(14):1647–1657. doi:10.1001/jama.295.14.1647

    PubMed  Article  CAS  Google Scholar 

  44. 44.

    Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA (2003) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21(23):4314–4321. doi:10.1200/JCO.2003.05.151

    PubMed  Article  CAS  Google Scholar 

  45. 45.

    Reeves GK, Pirie K, Green J, Bull D, Beral V (2011) Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer. doi:10.1002/ijc.26460

  46. 46.

    Burrell HC, Pinder SE, Wilson AR, Evans AJ, Yeoman LJ, Elston CW, Ellis IO (1996) The positive predictive value of mammographic signs: a review of 425 non-palpable breast lesions. Clin Radiol 51(4):277–281

    PubMed  Article  CAS  Google Scholar 

  47. 47.

    Cherel P, Becette V, Hagay C (2005) Stellate images: anatomic and radiologic correlations. Eur J Radiol 54(1):37–54. doi:10.1016/j.ejrad.2004.11.018

    PubMed  Article  CAS  Google Scholar 

  48. 48.

    Cui Y, Page DL, Lane DS, Rohan TE (2009) Menstrual and reproductive history, postmenopausal hormone use, and risk of benign proliferative epithelial disorders of the breast: a cohort study. Breast Cancer Res Treat 114(1):113–120. doi:10.1007/s10549-008-9973-9

    PubMed  Article  Google Scholar 

  49. 49.

    Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M, Wassertheil-Smoller S, Page DL (2008) Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst 100(8):563–571. doi:10.1093/jnci/djn075

    PubMed  Article  CAS  Google Scholar 

  50. 50.

    Maxwell CJ, Bancej CM, Snider J (2001) Predictors of mammography use among Canadian women aged 50–69: findings from the 1996/97 National population health survey. CMAJ 164(3):329–334

    PubMed  CAS  Google Scholar 

  51. 51.

    Roder D, Houssami N, Farshid G, Gill G, Luke C, Downey P, Beckmann K, Iosifidis P, Grieve L, Williamson L (2008) Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mammography screening in Australia. Breast Cancer Res Treat 108(3):409–416. doi:10.1007/s10549-007-9609-5

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

This study was funded by the National Breast Cancer Foundation. The authors wish to acknowledge Ms Jill Rogers from Breast Screen SA who assembled the data set used for this research project. We also wish to acknowledge the contributions of past and current staff including data managers, radiologists, pathologists, and surgeons working at BSSA, as well as the support of the General Manager Ms Lou Williamson.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kerri R. Beckmann.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Beckmann, K.R., Farshid, G., Roder, D.M. et al. Impact of hormone replacement therapy use on mammographic screening outcomes. Cancer Causes Control 24, 1417–1426 (2013). https://doi.org/10.1007/s10552-013-0221-1

Download citation

Keywords

  • Hormone replacement therapy
  • Mammography
  • Screening
  • Breast neoplasm